{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:45:34Z","timestamp":1753890334143,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cutaneous immune-mediated adverse drug reactions are more prevalent in people with human immunodeficiency virus (PWH). Severe cutaneous adverse drug reactions (SCAR) are a life-threatening subset of cutaneous adverse drug reactions (CADRs) and a significant public health issue in settings endemic for human immunodeficiency virus and tuberculosis. However, limited data are available on CADR requiring hospitalisation in African settings. The aim of this study is to describe the epidemiology, offending drugs and outcomes of CADRs requiring admission to a South African tertiary dermatology service.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective folder review was conducted on all CADRs requiring hospitalisation at Nelson Mandela Academic Hospital in Mthatha, Eastern Cape, South Africa between 30 July 2015 and 15 December 2022. This data was compared to prospective inclusion of CADR admissions between 03 March 2021 and 09 April 2024 as part of the Immune-Mediated Adverse Drug Reactions (IMARI) Registry and Biorepository and AFRISCAR consortium. Where possible, phenotype and drug causality assessment was performed through RegiSCAR, or Naranjo and\/or ALDEN scoring respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CADR admissions included 122 cases: 89 and 33 in the retrospective and prospective cohorts respectively. The commonest SCAR phenotype was Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN) at 59.8% (73\/122), although other validated SCAR phenotypes included drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) and generalized fixed bullous drug eruption (GBFDE). Cutaneous presentations included typical and atypical SCAR features against a background Fitzpatrick skin tones of type IV and above. Amongst the retrospective cohort 16.9% (15\/89) of phenotypes were unclassifiable due to lack of photographs. The overall median (IQR) age was 38 (25\u201350) years, 50.8% (62\/122) were male and 60.7% (74\/122) were PWH [median (IQR) CD4T-cell count of 267 (76\u2013470) cells\/mm<jats:sup>3<\/jats:sup>]. The commonest offending drugs included cotrimoxazole in 24.6% (30\/122); and anti-retroviral therapy (ART) in 13.9% (17\/122). No offending drug could be identified in 24.7% (22\/89) of the retrospective cohort. The median (IQR) length of hospital stay for validated SCAR was 13 (8\u201321) days for the retrospective cohort and 19 (13\u201328) days for the prospective cohort (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). The median (IQR) length of hospital stay for non-SCAR was 9 (5\u201313) days for the retrospective cohort and 11 (9\u201316) days for the prospective cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Typical and atypical presentations of SCAR were represented in this vulnerable South African cohort of predominantly PWH. SJS\/TEN was the commonest phenotype, and cotrimoxazole the most frequent offending drug. This data emphasises the need for prospective data collection across a diverse African population for valid SCAR phenotyping and drug causality assessment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2024.1481281","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:33:56Z","timestamp":1732775636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Spectrum of offending drugs and cutaneous adverse drug reactions requiring hospitalisation in a tertiary South African hospital in TB\/HIV endemic setting"],"prefix":"10.3389","volume":"5","author":[{"given":"S. P. P.","family":"Konyana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. F.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Pirjol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Thwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Nkoyane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gxolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Lehloenya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mankahla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(15)00151-8","article-title":"Tuberculosis","volume":"387","author":"Dheda","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future","volume":"10","author":"Lehloenya","year":"2012","journal-title":"Expert Rev Anti-Infect Ther"},{"year":"","key":"B3","article-title":"RegiSCAR"},{"key":"B4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.923991","article-title":"Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions","volume":"9","author":"Copaescu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2332\/allergolint.55.1","article-title":"Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses","volume":"55","author":"Shiohara","year":"2006","journal-title":"Allergol Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3390\/ijms22042147","article-title":"Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS)","volume":"22","author":"Miyagawa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100374","DOI":"10.1016\/j.jctube.2023.100374","article-title":"Long-term HIV and tuberculosis outcomes in patients hospitalised with severe cutaneous adverse reactions","volume":"32","author":"Veenstra","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.iac.2022.01.005","article-title":"Recognizing drug hypersensitivity in pigmented skin","volume":"42","author":"Lehloenya","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"B11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12016-022-08924","article-title":"The role of patch testing in evaluating delayed hypersensitivity reactions to medications","volume":"63","author":"Woodruff","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"832048","DOI":"10.3389\/fphar.2022.832048","article-title":"Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics","volume":"13","author":"Tempark","year":"2022","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1016\/j.jid.2022.05.1059","article-title":"IFN-\u03b3 ELISpot in severe cutaneous adverse reactions to first-line antituberculosis drugs in an HIV endemic setting","volume":"142","author":"Porter","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00042560-200008010-00007","article-title":"Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for pneumocystis carinii pneumonia: AIDS clinical trials group 268","volume":"24","author":"Para","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"year":"","key":"B17","article-title":"Fogarty HIV-associated Tuberculosis Training Program. 2018 (cited 2024 July 25)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"441.8","DOI":"10.1001\/jamadermatol.2017.6484","article-title":"Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions","volume":"154","author":"Tangamornsuksan","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661135","article-title":"HLA-B*13:01 is a predictive marker of dapsone-induced severe cutaneous adverse reactions in Thai patients","volume":"12","author":"Satapornpong","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658593","article-title":"Characterization of T-cell responses to SMX and SMX-NO in co-trimoxazole hypersensitivity patients expressing HLA-B*13:01","volume":"12","author":"Pratoomwun","year":"2021","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/ACI.0000000000000545","article-title":"Drug hypersensitivity in HIV infection","volume":"19","author":"Peter","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/s0190-9622(97)70295-0","article-title":"Correlation of skin disorders with CD4 lymphocyte counts in patients with HIV\/AIDS","volume":"36","author":"Goldstein","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1056\/NEJMra2308181","article-title":"HIV-Associated Tuberculosis","volume":"391","author":"Meintjes","year":"2024","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jdin.2023.06.014","article-title":"Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome","volume":"13","author":"Wasuwanich","year":"2023","journal-title":"JAAD Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jaip.2024.05.045","article-title":"First-line anti-tuberculosis drug challenge reactions in DRESS in an HIV endemic setting","volume":"12","author":"Porter","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00149-9","article-title":"Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017\u201319: a multistage, cluster-based, cross-sectional survey","volume":"22","author":"Moyo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.humimm.2018.01.004","article-title":"Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester region of the western cape province of South Africa","volume":"79","author":"Grifoni","year":"2018","journal-title":"Hum Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.711944","article-title":"High resolution HLA \u223cA, \u223cB, \u223cC, \u223cDRB1, \u223cDQA1, and \u223cDQB1 diversity in South African populations","volume":"13","author":"Tshabalala","year":"2022","journal-title":"Front Genet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.humimm.2019.12.003","article-title":"Human leukocyte antigen class I (A, B, C) and class II (DPB1, DQB1, DRB1) allele and haplotype variation in black South African individuals","volume":"81","author":"Loubser","year":"2020","journal-title":"Hum Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.mjafi.2013.01.007","article-title":"Severe cutaneous adverse drug reactions","volume":"69","author":"Verna","year":"2013","journal-title":"Med J Armed Forces India"},{"key":"B32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000248311","article-title":"Gender-based differences in drug prescription: relation to adverse drug reactions","volume":"84","author":"Zopf","year":"2009","journal-title":"Pharmacology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.jaip.2020.12.052","article-title":"The role of in vivo and ex vivo diagnostic tools in severe delayed immune-mediated adverse antibiotic drug reactions","volume":"9","author":"Copaescu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jdermsci.2021.09.008","article-title":"Corrigendum to \u201cSJS\/TEN 2019: from science to translation\u201d [J. Dermatol. Sci. 98\/1 (2020) 2\u201312]","volume":"104","author":"Chang","year":"2021","journal-title":"J Dermatol Sci"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1481281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:34:01Z","timestamp":1732775641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1481281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":37,"alternative-id":["10.3389\/falgy.2024.1481281"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1481281","relation":{},"ISSN":["2673-6101"],"issn-type":[{"type":"electronic","value":"2673-6101"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"article-number":"1481281"}}